200 related articles for article (PubMed ID: 25100847)
1. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic hepatitis C virus infection.
Hou J; van Oord G; Groothuismink ZM; Claassen MA; Kreefft K; Zaaraoui-Boutahar F; van IJcken WF; Osterhaus AD; Janssen HL; Andeweg AC; de Knegt RJ; Boonstra A
J Virol; 2014 Nov; 88(21):12254-64. PubMed ID: 25100847
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus load and expression of a unique subset of cellular genes in circulating lymphoid cells differentiate non-responders from responders to pegylated interferon alpha-ribavirin treatment.
Pham TN; Lin DM; Mulrooney-Cousins PM; Churchill ND; Kowala-Piaskowska A; Mozer-Lisewska I; Machaj A; Pazgan-Simon M; Zalewska M; Simon K; King D; Reddy SB; Michalak TI
J Med Virol; 2013 Mar; 85(3):441-8. PubMed ID: 23280583
[TBL] [Abstract][Full Text] [Related]
3. IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNα 2b and ribavirin in patients with hepatitis C virus genotype 1.
Sixtos-Alonso MS; Sánchez-Muñoz F; Sánchez-Ávila JF; Martínez RA; Domínguez López A; Vargas Vorácková F; Uribe M
Arch Med Res; 2011 Jan; 42(1):28-33. PubMed ID: 21376259
[TBL] [Abstract][Full Text] [Related]
4. mRNA cytokine profile in peripheral blood cells from chronic hepatitis C virus (HCV)-infected patients: effects of interferon-alpha (IFN-alpha) treatment.
Shapiro S; Gershtein V; Elias N; Zuckerman E; Salman N; Lahat N
Clin Exp Immunol; 1998 Oct; 114(1):55-60. PubMed ID: 9764603
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-co-infected non-responders and relapsers to IFN-based therapy.
Myers RP; Benhamou Y; Bochet M; Thibault V; Mehri D; Poynard T
AIDS; 2004 Jan; 18(1):75-9. PubMed ID: 15090832
[TBL] [Abstract][Full Text] [Related]
6. Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients.
Rallon NI; Lopez-Fernandez LA; Garcia MI; Benguria A; Fiorante S; Soriano V; Benito JM
AIDS; 2013 Mar; 27(5):687-96. PubMed ID: 23196939
[TBL] [Abstract][Full Text] [Related]
7. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
[TBL] [Abstract][Full Text] [Related]
8. Viral and host factors in the prediction of response to interferon-alpha therapy in chronic hepatitis C after long-term follow-up.
Knolle PA; Kremp S; Höhler T; Krummenauer F; Schirmacher P; Gerken G
J Viral Hepat; 1998 Nov; 5(6):399-406. PubMed ID: 9857349
[TBL] [Abstract][Full Text] [Related]
9. HCV RNA levels during therapy with amantadine in addition to interferon and ribavirin in chronic hepatitis C patients with previous nonresponse or response/relapse to interferon and ribavirin.
Carlsson T; Lindahl K; Schvarcz R; Wejstal R; Uhnoo I; Shev S; Reichard O
J Viral Hepat; 2000 Nov; 7(6):409-13. PubMed ID: 11115051
[TBL] [Abstract][Full Text] [Related]
10. [Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin].
Li QR; Zhang CJ; Xiong YL; Zhu Y; Tan ZX; Hu YJ; Yuan J; Wang XH
Zhonghua Gan Zang Bing Za Zhi; 2012 May; 20(5):353-6. PubMed ID: 22971280
[TBL] [Abstract][Full Text] [Related]
11. Study of the effect of antiviral therapy on homocysteinemia in hepatitis C virus- infected patients.
Mustafa M; Hussain S; Qureshi S; Malik SA; Kazmi AR; Naeem M
BMC Gastroenterol; 2012 Aug; 12():117. PubMed ID: 22925702
[TBL] [Abstract][Full Text] [Related]
12. Liver expression of proteins controlling interferon-mediated signalling as predictive factors in the response to therapy in patients with hepatitis C virus infection.
Bautista D; Bermúdez-Silva FJ; Lasarte JJ; Rodriguez-Fonseca F; Baixeras E
J Pathol; 2007 Nov; 213(3):347-55. PubMed ID: 17940994
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
14. Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients.
Odigie M; Osinusi A; Barrett L; Townsend K; Wang H; Suffredini AF; Masur H; Polis MA; Kottilil S
AIDS Res Hum Retroviruses; 2014 Aug; 30(8):775-82. PubMed ID: 24856902
[TBL] [Abstract][Full Text] [Related]
15. Complete eradication of hepatitis C virus after interferon treatment for chronic hepatitis C.
De Mitri MS; Morsica G; Chen CH; Mele L; Baccarini P; Chianese R; Piccinini A; Lazzarin A; Pisi E
Ital J Gastroenterol Hepatol; 1997 Jun; 29(3):255-61. PubMed ID: 9646218
[TBL] [Abstract][Full Text] [Related]
16. Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24 h.
Devitt E; Lawless MW; Sadlier D; Browne JA; Walsh C; Crowe J
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1211-20. PubMed ID: 20631625
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children.
El Naghi S; Abdel-Ghaffar TY; El-Karaksy H; Abdel-Aty EF; El-Raziky MS; Allam AA; Helmy H; El-Araby HA; Behairy BE; El-Guindi MA; El-Sebaie H; Abdel-Ghaffar AY; Ehsan NA; El-Hennawy AM; Sira MM
World J Gastroenterol; 2014 Apr; 20(16):4681-91. PubMed ID: 24782620
[TBL] [Abstract][Full Text] [Related]
18. Interferon-γ-stimulated genes, but not USP18, are expressed in livers of patients with acute hepatitis C.
Dill MT; Makowska Z; Duong FHT; Merkofer F; Filipowicz M; Baumert TF; Tornillo L; Terracciano L; Heim MH
Gastroenterology; 2012 Sep; 143(3):777-786.e6. PubMed ID: 22677194
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment.
Campistol JM; Esforzado N; Martínez J; Roselló L; Veciana L; Modol J; Casellas J; Pons M; de Las Cuevas X; Piera J; Oliva JA; Costa J; Barrera JM; Bruguera M
Nephrol Dial Transplant; 1999 Nov; 14(11):2704-9. PubMed ID: 10534516
[TBL] [Abstract][Full Text] [Related]
20. Long-term retreatment in chronic hepatitis C patients who were non-responders to an initial course of interferon-alpha 2b.
Tong MJ; Blatt LM; Tong LT; Sayadzadeh K; Conrad A
J Viral Hepat; 1998 Sep; 5(5):323-31. PubMed ID: 9795916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
